"Sunvou and Sanofi Collaborate to Advance Precision Diagnosis and Treatment for Asthma Patients"

During the exhibition, Sunvou Medical and Sanofi jointly launched the "Asthma Patient-Centered Precision Diagnosis and Treatment" cooperation initiative. Current asthma control levels worldwide remain a significant challenge, with 55-70% of asthma patients in China experiencing poor disease management, resulting in a heavy burden on patients. At the meeting, Professor Zhou Xin of the First People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine introduced the "FeNO Detection and Biological Agents Application Initiative in the Precision Diagnosis and Treatment of Type 2 Asthma." Professor Zhou highlighted the clinical importance of FeNO detection as a convenient, non-invasive method for diagnosing and managing respiratory diseases. Under this initiative, it is anticipated that new detection methods and treatment strategies will improve asthma management and protect airway health for millions of patients.